Preview Mode Links will not work in preview mode

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

Oct 24, 2018

In this interview, Eric L. Michelson and Brendan Everett discuss anti-inflammatory therapy with canakinumab and incident type 2 diabetes: a prespecified key secondary endpoint of CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study).